Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Cancer Specialists Back New Treatment For UK Patients
Trial reports of the Evolife range of products in France have pointed to significant benefits and enhanced quality of life for cancer patients who use the products before, during and after chemo or radiotherapy treatment. Evolife is a natural range of cosmetics that is 100% dedicated to the support care of cancer patients.
generic viagra online
New FDA Records Obtained By Judicial Watch Indicate 28 Deaths Related To Gardasil In 2008
Judicial Watch, the public interest group that investigates and prosecutes government corruption, announced today that it has obtained records from the Food and Drug Administration (FDA) documenting 28 deaths in 2008 associated with Gardasil, the vaccination for human papillomavirus (HPV), up from the 19 deaths in 2007. The total number of Gardasil-related deaths is 47 since the vaccine was approved in 2006. Overall, the FDA documented 6,723 "adverse events" related to Gardasil in 2008, of which 1,061 were considered "serious," and 142 considered "life threatening."
News of the day
Plexxikon Announces PLX4032 Phase 1 Data Showing Objective Responses In Metastatic Melanoma Patients
Plexxikon Inc. today announced preliminary data from a Phase 1 clinical study investigating PLX4032 (R7204). PLX4032 is a novel, oral and highly selective drug that targets the BRAFV600E cancer-causing mutation that occurs in most melanomas and about eight percent of all solid tumors. In patients whose cancer harbors this mutation and who were treated with therapeutic doses of PLX4032, tumor shrinkage and extended progression-free survival have been observed. Currently, two extension studies are being conducted in mutation-positive melanoma and colorectal cancer patients. Following the initial positive findings announced today, larger clinical trials to support a registration program for product approval are targeted to start later in 2009. Plexxikon and Roche are co-developing PLX4032 under their 2006 license and collaboration agreement.
Endocrinology

Consumers Rate Medicare Higher Than Employer-Sponsored Insurance

Elderly Medicare beneficiaries are more satisfied with their health care, and experience fewer problems accessing and paying for care, than Americans with employer-sponsored insurance (ESI), according to a study by Commonwealth Fund researchers published May 12 on the Health Affairs Web site. If given the opportunity, many adults under age 65 would likely select a public health insurance option, say lead author Karen Davis, president of the Commonwealth Fund, and colleagues. The study is based on data from the Commonwealth Fund 2007 Biennial Health Insurance Survey, a nationally representative survey of 3,501 adults age 19 and older conducted between June 4 and October 24, 2007. The gap between consumers" ratings of Medicare and ESI has widened since a similar survey in 2001. Health Affairs


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009